menu
    • menu
    [{"orgOrder":0,"company":"United Biomedical","sponsor":"Vaxxinity","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United Biomedical \/ United Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"United Biomedical \/ United Biomedical"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Vaxxinity","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Biomedical \/ Vaxxinity","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Vaxxinity"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Vaxxinity","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Biomedical \/ Vaxxinity","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Vaxxinity"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Vaxxinity","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Biomedical \/ Vaxxinity","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Vaxxinity"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Biomedical \/ Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia"},{"orgOrder":0,"company":"United Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"United Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"United Biomedical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by United Biomedical

    Menu

    United Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines...

                            Details : UB-612 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 22, 2021

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

                            Details : UB-612 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 20, 2021

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers

                            Details : UB-612 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 26, 2021

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate Against COVID-19

                            Details : Taiwan Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 02, 2021

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

                            Details : UB-612 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 11, 2020

                            Lead Product(s) : UB-612

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaxxinity

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-421

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults

                            Details : UB-421 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 17, 2012

                            Lead Product(s) : UB-421

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Taipei Veterans General Hospital | Kaohsiung Veterans General Hospital. | United Biomedical Inc., Asia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Biomedical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UB-421

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Pharmacokinetics of UB-421 Antibody in HIV-1 Infected Adults

                            Details : UB-421 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 09, 2010

                            Lead Product(s) : UB-421

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth